Novoron Bioscience Overview
- Year Founded
-
2014
- Status
-
Private
- Employees
-
17
- Latest Deal Type
-
Later Stage VC
- (In Progress)
- Investors
-
7
Novoron Bioscience General Information
Description
Operator of a biotechnology company intended to develop lipoprotein-receptor drugs to repair damage and degeneration of the brain. The company's current pipeline consists of pre-clinical therapies to address Alzheimer's disease, multiple sclerosis, spinal cord injury and, and beyond targeting both whole-receptor and micro-domain levels for Low-Density Lipoprotein Receptors (LDLRs), enabling patients suffering from conditions to recover faster from neurological damage and disease in the central nervous system (CNS).
Contact Information
Website
www.novoron.comCorporate Office
- 1155 Island Avenue
- Suite 100
- San Diego, CA 92101
- United States
Corporate Office
- 1155 Island Avenue
- Suite 100
- San Diego, CA 92101
- United States
Novoron Bioscience Timeline
Novoron Bioscience Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 18. Later Stage VC | 16-Dec-2024 | In Progress | Pre-Clinical Trials | |||
| 17. Seed Round | 19-Dec-2022 | Completed | Pre-Clinical Trials | |||
| 16. Grant | 22-Apr-2022 | Completed | Pre-Clinical Trials | |||
| 15. Grant | 07-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 14. Grant | 01-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 13. Grant | 01-Sep-2021 | Completed | Pre-Clinical Trials | |||
| 12. Seed Round | 07-Jul-2021 | Completed | Pre-Clinical Trials | |||
| 11. Grant | 01-Sep-2019 | Completed | Pre-Clinical Trials | |||
| 10. Grant | 01-Apr-2019 | $1.05M | Completed | Pre-Clinical Trials | ||
| 9. Grant | 01-Apr-2018 | $695K | Completed | Pre-Clinical Trials |
Novoron Bioscience Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Seed-1 | ||||||||
| Seed |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Novoron Bioscience Comparisons
Industry
Financing
Details
Novoron Bioscience Competitors (6)
One of Novoron Bioscience’s 6 competitors is Axonis Therapeutics, a Venture Capital-Backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Axonis Therapeutics | Venture Capital-Backed | Boston, MA | ||||
| BioAxone | Accelerator/Incubator Backed | Boston, MA | ||||
| ReNetX Bio | Venture Capital-Backed | New Haven, CT | ||||
| NervGen Pharma | Formerly Angel backed | Vancouver, Canada | ||||
| Contineum Therapeutics | Formerly VC-backed | San Diego, CA |
Novoron Bioscience Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Novoron Bioscience Patents
Novoron Bioscience Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-3433356-A1 | Methods and compositions for promoting opc differentiation and remyelination using receptor associated protein (rap) | Inactive | 21-Mar-2016 | ||
| US-20200397857-A1 | Methods and compositions for promoting opc differentiation and remyelination using receptor associated protein (rap) | Pending | 21-Mar-2016 | ||
| US-20190083571-A1 | Methods and compositions for promoting opc differentiation and remyelination using receptor associated protein (rap) | Inactive | 21-Mar-2016 | ||
| CA-3022269-A1 | Methods and compositions for promoting opc differentiation and remyelination using receptor associated protein (rap) | Pending | 21-Mar-2016 | A61K38/177 |
Novoron Bioscience Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Novoron Bioscience Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| National Institute On Aging | Government | |||
| Two Bear Capital | Venture Capital | Minority | ||
| U.S. Department of Health and Human Services | Government | |||
| RESI Conference Series | Other | |||
| Johnson & Johnson Innovation - JLABS | Accelerator/Incubator | Minority |
Novoron Bioscience FAQs
-
When was Novoron Bioscience founded?
Novoron Bioscience was founded in 2014.
-
Where is Novoron Bioscience headquartered?
Novoron Bioscience is headquartered in San Diego, CA.
-
What is the size of Novoron Bioscience?
Novoron Bioscience has 17 total employees.
-
What industry is Novoron Bioscience in?
Novoron Bioscience’s primary industry is Drug Discovery.
-
Is Novoron Bioscience a private or public company?
Novoron Bioscience is a Private company.
-
What is Novoron Bioscience’s current revenue?
The current revenue for Novoron Bioscience is .
-
How much funding has Novoron Bioscience raised over time?
Novoron Bioscience has raised $15.2M.
-
Who are Novoron Bioscience’s investors?
National Institute On Aging, Two Bear Capital, U.S. Department of Health and Human Services, RESI Conference Series, and Johnson & Johnson Innovation - JLABS are 5 of 7 investors who have invested in Novoron Bioscience.
-
Who are Novoron Bioscience’s competitors?
Axonis Therapeutics, BioAxone, ReNetX Bio, NervGen Pharma, and Contineum Therapeutics are some of the 6 competitors of Novoron Bioscience.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
